Skip to main navigation
Skip to search
Skip to main content
Technical University of Munich Home
Help & FAQ
English
Deutsch
Home
Profiles
Research units
Projects
Research output
Equipment
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Phage Therapy in Germany—Update 2023
Christian Willy
, Joachim J. Bugert
, Annika Y. Classen
,
Li Deng
, Anja Düchting
, Justus Gross
, Jens A. Hammerl
, Imke H.E. Korf
, Christian Kühn
, Simone Lieberknecht-Jouy
, Christine Rohde
, Markus Rupp
, Maria J.G.T. Vehreschild
, Kilian Vogele
, Sarah Wienecke
, Martin Witzenrath
, Silvia Würstle
, Holger Ziehr
, Karin Moelling
, Felix Broecker
Associate Professorship of Prevention of Microbial Diseases
Military Academic Hospital Berlin
Bundeswehr Institute of Microbiology
University Hospital of Cologne
Partner Site Bonn-Cologne
Helmholtz Zentrum München German Research Center for Environmental Health
Federal Institute for Drugs and Medical Devices (BfArM)
University Medical Centre Rostock
German Federal Institute for Risk Assessment (BfR)
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin
Hannover Medical School
Klinikum der J. W. Goethe-Universität
Leibniz Institute
Klinikum der Universität Regensburg und Medizinische Fakultät
Technical University of Munich
Charité – Universitätsmedizin Berlin
Max Planck Institute for Molecular Genetics
Idorsia (Berlin) Pharmaceuticals GmbH
Research output
:
Contribution to journal
›
Article
›
peer-review
29
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Phage Therapy in Germany—Update 2023'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Phage Therapy
100%
Germany
80%
Clinical Application
60%
Translational Research
40%
Phage
40%
Phage Bank
40%
Phage Production
40%
Medicinal Products
20%
Regulatory Agencies
20%
Medical Field
20%
Clinical Trials
20%
Patient-centered
20%
Group Work
20%
Paucity
20%
Network Structure
20%
Antibiotic Resistance
20%
Production Capacity
20%
One-site
20%
Belgian
20%
Good Manufacturing Practice
20%
Interdisciplinary Group
20%
Bacteriophage
20%
Restricted Use
20%
Structured Networks
20%
Susceptibility Testing
20%
Institutional Policy
20%
Therapeutic Guidelines
20%
Bacteriophage Therapy
20%
Policy Exchange
20%
Number of Patients
20%
Phage Application
20%
Individual Treatment Trials
20%
Medicine and Dentistry
Phage Therapy
100%
Bacteriophage
100%
Translational Research
25%
Clinical Trial
12%
Antibiotic Resistance
12%
Pharmacology, Toxicology and Pharmaceutical Science
Bacteriophage
100%
Clinical Trial
7%
Good Manufacturing Practice
7%
Antibiotic Resistance
7%